Pfizer Inc.

Novartis said on Sunday that Kisqali helped women with advanced breast cancer after menopause live longer, adding to data the Swiss company hopes will help convince doctors to choose its drug over Pfizer's blockbuster Ibrance.

Pfizer Inc <PFE.N> said on Friday Ian Read will retire as executive chairman at the end of this year, after a four-decade association with the largest U.S. drugmaker that included eight years as chief executive officer.

Pfizer Inc said on Friday Ian Read will retire as executive chairman at the end of this year, ending a four-decade association with the largest U.S. drugmaker.

British fashion retailer Ted Baker Plc <TED.L> said on Thursday Rachel Osborne will become its new finance chief once she steps down from the same position at Debenhams, following just one year in the role at the department store chain.

Novartis <NOVN.S> has secured the U.S. Food and Drug Administration's Breakthrough Therapy Designation for its investigational medicine capmatinib, which it aims to file for approval later this year against a mutated form of lung cancer.

Novartis has nabbed the U.S. Food and Drug Administration's breakthrough therapy designation for its experimental medicine capmatinib as it joins Pfizer in the race to treat a tough-to-treat mutated lung cancer type.

Pfizer Inc is investing $500 million to expand a manufacturing facility in Sanford, North Carolina, that plays a central role in its efforts to become a major player in gene therapy, the company said on Wednesday.

The Federal Trade Commission issued civil subpoenas to Johnson and Johnson in June as part of an investigation into whether contracting practices for its blockbuster rheumatoid arthritis drug, Remicade, violated antitrust laws, the company said in a regulatory filing on...

Mylan NV's <MYL.O> planned merger with Pfizer Inc's <PFE.N> off-patent branded drugs business may have boosted its share price on Monday, but one of its most pressing problems remains: shortages of its flagship EpiPen emergency allergy treatment.

Mylan NV's <MYL.O> planned merger with Pfizer Inc's <PFE.N> off-patent branded drugs business may have boosted its share price on Monday, but one of its most pressing problems remains: shortages of its flagship EpiPen emergency allergy treatment.

Pfizer Inc <PFE.N> has agreed to spin off its off-patent branded drugs business and combine it with generic drugmaker Mylan NV <MYL.O>, a move that leaves Pfizer with its more profitable innovative drugs, including cancer treatment Ibrance and pneumonia vaccine Prevnar.

The following bids, mergers, acquisitions and disposals were reported by 2025 GMT on Monday:

Pfizer Inc is in talks to merge its contract manufacturer that produces Mylan's EpiPen emergency allergy treatment into the new generics business it has created by combining its older off-patent medicines unit with generic drugmaker Mylan NV, a Pfizer spokeswoman said.

Pfizer Inc <PFE.N> on Monday reported a 30% rise in quarterly profit, helped by demand for its branded treatments such as Ibrance, Eliquis and Xeljanz.

Mylan NV said on Monday it would combine with Pfizer Inc's off-patent branded and generic established medicines business to form a global generic drugmaker.

Pfizer Inc <PFE.N> is in talks to merge its off-patent drugs business with Mylan NV <MYL.O> in a stock deal, according to a source familiar with the matter.

Pfizer Inc is in talks to merge its off-patent drugs business with Mylan NV in a stock deal, the Wall Street Journal reported on Saturday, citing people familiar with the matter.

U.S. Senator Elizabeth Warren urged former U.S. Food and Drug Administration Commissioner Scott Gottlieb to immediately step down from Pfizer Inc's <PFE.N> board, three months after his departure from the health regulator.

South Africa's Biovac Institute will start local production of Sanofi's Hexaxim vaccine next year and Pfizer's anti-pneumonia Prevnar 13 vaccine in 2021, boosting supply of life-saving drugs in its main market, its CEO said.